Pralatrexate
- TRADE NAME: Folotyn (Allos)
- INDICATIONS: Relapsed or refractory peripheral T-cell lymphoma
- CLASS: Folate analogue metabolic inhibitor
- HALF-LIFE: 12–18 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
BCG Vaccine, Cardiac glycosides, Denosumab, Echinacea, Leflunomide, Meloxicam, Natalizumab, NSAIDs, Pimecrolimus, Probenecid, Roflumilast, Salicylates, Sapropterin, Sipuleucel-T, Sulfamethoxazole, Tacrolimus, Trastuzumab, Trimethoprim, Vaccines, Vitamin K antagonists
PREGNANCY CATEGORY: D
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 08/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
